Intraoperative Flowmetry Provides Quality Assurance during Coronary Artery Bypass Grafting Surgery (EP Video)
Coupled with a flow sensor on the heart lung machine to verify delivered cardioplegia flow, flow measurements during CABG provide a dual measure of quality assurance (9:57 minutes).
Surgical Treatment of End Stage Heart Failure (EP Video)
Dr. Caldeira discusses the surgical treatment options for end stage heart failure (33:02 minutes).
Mechanism of Action of Anti-Thrombin (EP Video)
Grifols provides a product overview of Thrombate: indications, dosing and administration and how it is supplied (8:27 minutes).
A Clinical Approach to Attenuate Hyperkalemia During Cardiopulmonary Bypass (EP Video)
Hyperkalemia during cardiopulmonary bypass (CPB) is a relatively frequent occurrence and is associated with decreased kidney perfusion and introduction of potassium (K+) during cardioplegia administration (22:11 minutes).
Custodiol HTK Solution (EP Video)
Alan Weber from Essential Pharmaceutical presents on Custodiol HTK solution (5:51 minutes).
The Effects of Cardiopulmonary Bypass on Renal Function (EP Video)
After conducting this study the investigators hope to identify the CPB factors which have a direct effect on renal function (13:18 minutes).
Open Forum on Platelet Therapy & Clinical & Feasible Regenerative Medicine Treatment Options in the OR (EP Video)
The regenerative medicine market today includes first of all platelet-rich plasma (PRP) products, brought to market by a large variety of medical companies (52:34 minutes).
TEG use in CV & Trauma Cases (EP Video)
This program will provide a basic overview of the TEG Hemostasis Analyzer and then focus on case studies in CV surgery, CV patient stratification, Trauma cases and a case study on Pradaxa (42:50 minutes).
Cytomedix PRP Technology & Blood Management (EP Video)
Thomas Johnston discusses PRP technology on behalf of Cytomedix (13:30 minutes).
Transmyocardial Laser Revascularization Past, Present & Future (EP Video)
Transmyocardial Laser Revascularization (TMR) remains an important treatment option for advanced coronary artery disease(42:32 minutes).